The use of combined xanthine oxidase inhibitors (febuxostat) with a uricosuric agent (lesinurad) has shown long term safety and efficacy in patients with tophaceous gout in a trial involving Australian centres. In a two year follow up study, febuxostat and lesinurad were effective in lowering serum urate levels, reducing gout flares and decreasing the size ...
Combo therapy kicks urate target goals
By Mardi Chapman
29 Jan 2019